Consolidated figures · ₹ crore
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 198 | 215 | 234 | 273 | 312 | 368 | |
| COGS | 107 | 94 | 115 | 140 | 160 | 188 |
| Gross profit | 91 | 121 | 120 | 133 | 151 | 180 |
| 53 | 74 | 77 | 94 | 111 | 134 | |
| 38 | 47 | 43 | 39 | 40 | 46 | |
| OPM % | 19.2% | 21.8% | 18.3% | 14.4% | 12.9% | 12.4% |
| Depreciation | 9 | 11 | 12 | 12 | 16 | 19 |
| Interest | 2 | 3 | 4 | 8 | 9 | 10 |
| 1 | 4 | 5 | 4 | 8 | 4 | |
| Profit before tax | 29 | 37 | 32 | 23 | 23 | 21 |
| Tax | 4 | 3 | 2 | 5 | 3 | 4 |
| Tax % | 14.7% | 7.3% | 5.8% | 21.9% | 12.7% | 16.3% |
| 25 | 34 | 30 | 18 | 20 | 18 | |
| PAT margin % | 12.5% | 16% | 12.7% | 6.6% | 6.6% | 4.9% |
| EPS (₹) | — | 18.1 | 15 | 10.8 | 10.6 | 7.7 |
| EPS adjusted (₹) | 17.9 | 23.7 | 20.6 | 10.5 | 10.6 | 7.7 |
| — | 2.8% | 3.3% | 4.7% | 4.7% | 6.5% | |
| Annual report | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 7 | 7 | 7 | 8 | 8 | 8 |
| Reserves | 172 | 280 | 353 | 500 | 528 | 591 |
| Minority interest | 80 | 77 | 59 | — | — | — |
| 29 | 38 | 58 | 76 | 94 | 114 | |
| 75 | 85 | 101 | 109 | 104 | 106 | |
| Total equity & liabilities | 363 | 488 | 578 | 692 | 734 | 819 |
| 210 | 221 | 218 | 214 | 336 | 335 | |
| CWIP | 0 | 3 | 57 | 117 | — | — |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| 153 | 264 | 303 | 362 | 398 | 484 | |
| Total assets | 363 | 488 | 578 | 692 | 734 | 819 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 59 | 10 | -19 | -6 | -8 | -34 | |
| -65 | -23 | -71 | -86 | -13 | -21 | |
| 2 | 79 | 50 | 99 | 10 | 62 | |
| Net cash flow | -4 | 66 | -40 | 7 | -10 | 6 |
| Free cash flow | -6 | -15 | -82 | -86 | -28 | -57 |
| CFO / Operating profit % | 154.9% | 21.2% | -44.1% | -16.2% | -18.9% | -74.2% |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Pharma Formulation | 197.77 | 15.48 | 356.09 | 48.47 | 307.62 | 5.03 |
| Agrochemicals | 151.26 | 22.02 |
| 317.12 |
| 59.78 |
| 257.34 |
| 8.56 |
| Unallacated other operating revenue | 9.93 | 0 | 0 | 0 | — | — |
| Active Pharma Ingredient (API) | 9.05 | -6.43 | 125.69 | 12.1 | 113.59 | -5.66 |
₹ crore by fiscal year